The publication on “Effects of vaccination on acute exacerbation of chronic obstructive pulmonary disease: a nationwide population-based cohort study [
1].” The impact of the coronavirus disease 2019 (COVID-19) vaccine on lowering acute exacerbation of chronic obstructive pulmonary disease (AECOPD), a major concern for patients with chronic obstructive pulmonary disease (COPD), was examined in this study. Nonetheless, there are still some dubious parts of the study’s methodology and findings.
First, a comparable sample of vaccinated and unvaccinated groups was created using propensity score matching. This method lessens selection bias, but it doesn’t account for all unmeasured variables that can have an impact on the study’s findings, like socioeconomic status, comorbidities, or access to healthcare. Examining how well the matching can lessen bias from these aspects is crucial.
In terms of statistical analysis, the use of Cox proportional hazards regression models is appropriate to assess the risk of AECOPD, but the lack of information on the proportional hazards assumption test makes the results unclear. The interpretation of the results in the vaccinated group, especially in the absence of a significant difference in risk (hazard ratio, 1.35; 95% confidence interval, 0.42 to 4.36), may indicate that the sample size may not be sufficient to detect a statistically meaningful difference. This requires further study in a larger sample size.
Innovation-wise, a study like this might be used in Thailand, particularly with Thai patients who suffer from COPD. Examining how the COVID-19 vaccine affects Thai COPD patients may yield valuable data for national healthcare planning, which may include addressing the long-term effects of COVID-19 within the framework of the Thai healthcare system. Additionally, research on the effects of immunization on COPD patients who have linguistic and cultural barriers may contribute to a deeper comprehension of this patient population.